.png)
R&D Pipeline
A comprehensive overview of our clinical development stages and strategic research initiatives.
Discovery
Non-Clinical
Phase I
Phase II
Phase III
Approval
Launch
EuHZV
EuRSV
Padivax™
Herpes Zoster Virus
(EuHZV)
Shingles can be a serious condition, especially for older adults and people with weakened immune systems. EuHZV is currently undergoing Phase 1 evaluation.
Respiratory Syncytial Virus
(EuRSV)
EuPOP's lead candidate, currently in Phase 1 clinical studies in Korea, EuRSV, seeks to address the significant unmet medical need among pediatric and elderly populations for an effective vaccine against RSV.
Alzheimer's Disease (Padivax™)
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder in the world (47 million people affected). Leveraging its proprietary ECLS technology, EuPOP is exploring multi-antigen vaccine approaches that may address the complex and multifactorial nature of AD.
Peptide Vaccine (Planned)
Leveraging the versatile ECLS platform, EuPOP is exploring additional peptide vaccine opportunities across infectious diseases, cancer, and other areas of unmet medical need.